A phase 1 trial of PSCA-targeting CAR T cell therapy in patients with PSCA-positive, metastatic castration-resistant prostate cancer demonstrates that the treatment, using a protocol with reduced lymphodepletion, is safe and shows preliminary clinical activity.
- Tanya B. Dorff
- M. Suzette Blanchard
- Saul J. Priceman